Vical Incorporated (VICL), Bristol Myers Squibb Co. (BMY): This Biotech Stock Might Boost Your Portfolio

In terms of safety profile, I described above that Allovectin has no grade 3 or grade 4 adverse events. The problem with Yervoy is that there are mild adverse events. Bristol Myers Squibb Co. (NYSE:BMY) attributes these adverse events due T-cell activation and proliferation. So, Allovectin can gain an upper hand against Yervoy, considering it is also safer to use.

GlaxoSmithKline plc (ADR) (NYSE:GSK) joins the party

Well, GlaxoSmithKline plc (ADR) (NYSE:GSK) doesn’t want to let others lead over it in the melanoma market, as it has applied for FDA approval for both dabrafenib and trametinib. The company has also filed for dabrafenib in the EMA, and hopes to also add trametinib in the coming months.

In June 2012, 80% of patients with melanoma who took trametinib were alive at 6 months. That compared to only 67% of the patients alive at 6 months that took Chemotherapy alone.

In terms of dabrafenib, it had delayed disease progression of melanoma patients by 5.1 months. This compares better than patients on chemotherapy alone, which delayed disease progression by only 2.7 months.

Final thoughts

The space for the melanoma market is heating up, and I think that Vical can deliver on their phase 3 results of Allovectin. It will have to produce better results than big pharma companies like Bristol Myers Squibb Co. (NYSE:BMY), and GlaxoSmithKline. The good part about Vical is that their pipeline is pretty extensive.They are also targeting herpes simplex virus and the cytomegalovirus. The company uses its DNA vaccine technology to produce an assortment of vaccines against cancers and infectious diseases.

You can’t go wrong with this speculative play in your portfolio. Also, the success of Allovectin will prove that DNA vaccines are coming of age in the immunotherapy sector. This will show the science community that DNA vaccines can be used as a safe alternative to fight cancers and infectious diseases. So if all goes well, Vical can boost your portfolio.

The article This Biotech Stock Might Boost Your Portfolio originally appeared on Fool.com and is written by Terry Chrisomalis.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

6 Movies That You Should Watch to Better Understand The Cold War

Top 15 Best Paying Jobs for Women in 2014

Top 6 Things Rich People Do Differently Every Day

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top 6 Tax Scams and How to Protect Yourself

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!